{"generic":"Antihemophilic Factor VIII Human","drugs":["Antihemophilic Factor VIII Human","Koate DVI","Monoclate-P"],"mono":{"0":{"id":"qgss0","title":"Generic Names","mono":"Antihemophilic Factor VIII Human"},"1":{"id":"qgss1","title":"Dosing and Indications","sub":{"0":{"id":"qgss1b4","title":"Adult Dosing","mono":"<ul><li><b>Bleeding - Hemophilia A:<\/b> dosage calculation:  body weight (kg) X factor VIII activity increase desired (%) divided by 2% per international unit per kg = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A:<\/b> mild hemorrhage: a single dose of 10 international units\/kg IV to achieve a rise of approximately 20% of normal of antihemophilic factor VIII. Repeat if evidence of further bleeding<\/li><li><b>Bleeding - Hemophilia A:<\/b> moderate hemorrhage: 15 to 25 international units\/kg IV to achieve a rise of approximately 30% to 50% of normal of antihemophilic factor VIII. Repeat with 10 to 15 international units\/kg IV every 8 to 12 hours if evidence of further bleeding<\/li><li><b>Bleeding - Hemophilia A:<\/b> severe hemorrhage: initially 40 to 50 international units\/kg IV; maintenance dose 20 to 25 international units\/kg IV every 8 to 12 hours to achieve a rise of approximately 80% to 100% of normal of antihemophilic factor VIII<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> dosage calculation:  body weight (kg) X factor VIII activity increase desired (%) divided by 2% per international unit per kg = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> surgery, major procedures: preoperatively 50 international units\/kg IV to achieve a rise of approximately 100% of normal of antihemophilic factor VIII prior to surgery; repeat infusions every 6 to 12 hours initially as needed and for a total of 10 to 14 days until healing is complete<\/li><\/ul>"},"1":{"id":"qgss1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Bleeding - Hemophilia A:<\/b> dosage calculation:  body weight (kg) X factor VIII activity increase desired (%) divided by 2% per international unit per kg = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A:<\/b> mild hemorrhage: a single dose of 10 international units\/kg IV to achieve a rise of approximately 20% of normal of antihemophilic factor VIII. Repeat if evidence of further bleeding<\/li><li><b>Bleeding - Hemophilia A:<\/b> moderate hemorrhage: 15 to 25 international units\/kg IV to achieve a rise of approximately 30% to 50% of normal of antihemophilic factor VIII. Repeat with 10 to 15 international units\/kg IV every 8 to 12 hours if evidence of further bleeding<\/li><li><b>Bleeding - Hemophilia A:<\/b> severe hemorrhage: initially 40 to 50 international units\/kg IV; maintenance dose 20 to 25 international units\/kg IV every 8 to 12 hours to achieve a rise of approximately 80% to 100% of normal of antihemophilic factor VIII<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> dosage calculation:  body weight (kg) X factor VIII activity increase desired (%) divided by 2% per international unit per kg = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> surgery, major procedures: preoperatively 50 international units\/kg IV to achieve a rise of approximately 100% of normal of antihemophilic factor VIII prior to surgery; repeat infusions every 6 to 12 hours initially as needed and for a total of 10 to 14 days until healing is complete<\/li><\/ul>"},"3":{"id":"qgss1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding - Hemophilia A<\/li><li>Bleeding - Hemophilia A - Surgical procedure<\/li><\/ul>"}}},"3":{"id":"qgss3","title":"Contraindications\/Warnings","sub":[{"id":"qgss3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"qgss3b10","title":"Precautions","mono":"<ul><li>human plasma product; may contain infectious agents including viruses and theoretical risk of Creutzfeldt-Jakob disease agent<\/li><li>pregnant women and immunocompromised patients; parvovirus B19 transmission presents a more serious risk<\/li><li>report suspected transmission of infection to Talecris Biotherapeutics 1-800-520-2807<\/li><\/ul>"},{"id":"qgss3b11","title":"Pregnancy Category","mono":"Antihemophilic Factor: C (FDA)<br\/>"},{"id":"qgss3b12","title":"Breast Feeding","mono":"<ul><li>Antihemophilic Factor: WHO: Compatible with breastfeeding.<\/li><li>Antihemophilic Factor: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"qgss5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Ophthalmic:<\/b>Blurred vision<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Viral disease, Transmission<\/li><\/ul>"},"6":{"id":"qgss6","title":"Drug Name Info","sub":{"0":{"id":"qgss6b17","title":"US Trade Names","mono":"<ul><li>Koate DVI<\/li><li>Monoclate-P<\/li><\/ul>"},"2":{"id":"qgss6b19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"qgss6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"qgss6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"qgss7","title":"Mechanism Of Action","mono":"Antihemophilic Factor VIII Human is a dried concentrate of human Factor VIII, which facilitates the activation of Factor X ultimately causing the formation of thrombin and fibrin promoting platelet aggregation and adhesion to damaged vascular endothelium.<br\/>"},"8":{"id":"qgss8","title":"Pharmacokinetics","sub":{"4":{"id":"qgss8b27","title":"Elimination Half Life","mono":"16.12 hours <br\/>"}}},"9":{"id":"qgss9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>for IV administration only by either direct syringe injection or drip infusion<\/li><li>before reconstitution, warm supplied diluent to room temperature<\/li><li>during reconstitution, aim stream of diluent at a 45 degree angle against the side of vial to minimize foaming<\/li><li>administer using a filter needle<\/li><li>administer within 3 hours of reconstitution<\/li><li>administer at a rate tolerated by patient, usually entire dose in 5 to 10 minutes is well-tolerated<\/li><\/ul>"},"10":{"id":"qgss10","title":"Monitoring","mono":"<ul><li>plasma factor VIII levels; prior to administration to confirm cause of clotting disorder, and serial levels during treatment to determine adequate response, especially in the setting of surgical prophylaxis and severe bleeding<\/li><li>factor VIII inhibitor (neutralizing antibodies) levels; if inadequate response to appropriate doses<\/li><li>control of bleeding is indicative of efficacy<\/li><li>hematocrit levels and direct Coombs test; patients with blood type A, B, or AB receiving large or frequently repeated doses<\/li><\/ul>"},"11":{"id":"qgss11","title":"How Supplied","mono":"<b>Koate-DVI<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/>"},"13":{"id":"qgss13","title":"Clinical Teaching","mono":"<ul><li>Drug is made from human plasma. Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare provider, and patients receiving repeated\/regular therapy should consider appropriate vaccinations when possible (ie, hepatitis A and B).<\/li><li>Drug may cause headache, dizziness, dysgeusia, pyrexia, and infusion-site inflammation.<\/li><li>Instruct patients to report spontaneous bleeding episodes, as this may indicate the development of inhibitory antibodies against factor VIII.<\/li><li>Instruct patient to report signs\/symptoms of hepatitis A (several days to weeks of poor appetite, tiredness, and low-grade fever followed by nausea, vomiting, and pain in the belly). Dark urine and a yellowed complexion may also occur.<\/li><li>Advise pregnant women or immune compromised individuals of the signs\/symptoms of Parvovirus B19 (eg, fever, drowsiness, chills, and runny nose followed about two weeks later by a rash, and joint pain).<\/li><li>Advise patient to discontinue use and immediately report signs\/symptoms of hypersensitivity reactions (eg, hives, urticaria, facial edema, flushing, nausea, chest tightness, wheezing, dyspnea, hypotension, and anaphylaxis).<\/li><\/ul>"}}}